{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:02:51Z","timestamp":1772834571312,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.neuropharm.2018.06.038","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T17:17:45Z","timestamp":1530379065000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset"],"prefix":"10.1016","volume":"139","author":[{"given":"Adjia","family":"Hamadjida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen G.","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fleur","family":"Gaudette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Beaudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim C.","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.06.038_bib1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0014-2999(03)01992-7","article-title":"EMD 281014, a new selective serotonin 5-HT2A receptor antagonist","volume":"473","author":"Bartoszyk","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib3","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1523\/JNEUROSCI.4262-04.2005","article-title":"Amantadine inhibits NMDA receptors by accelerating channel closure during channel block","volume":"25","author":"Blanpied","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic mechanisms of l-dopa-induced dyskinesia: the findings, the debate, and the therapeutic implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.06.038_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/WNL.48.3.658","article-title":"Low-dose clozapine improves dyskinesias in Parkinson's disease","volume":"48","author":"Durif","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2018.06.038_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","article-title":"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease","volume":"37","author":"Fox","year":"2010","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib8","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson's disease. The French clozapine Parkinson study group","volume":"353","author":"French Clozapine Parkinson Study Group","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.06.038_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchromb.2017.07.007","article-title":"Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasma","volume":"1061\u20131062","author":"Gaudette","year":"2017","journal-title":"J.\u00a0Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2018.06.036","article-title":"Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset","author":"Gaudette","year":"2018","journal-title":"J.\u00a0Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib12","article-title":"Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease","author":"Hamadjida","year":"2017","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00213-017-4530-z","article-title":"The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset","volume":"234","author":"Hamadjida","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.06.038_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.pnpbp.2017.09.001","article-title":"The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset","volume":"81","author":"Hamadjida","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.06.038_bib15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib16","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib17","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","article-title":"Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in\u00a0vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of on-time","volume":"31","author":"Huot","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib18","doi-asserted-by":"crossref","first-page":"e45587","DOI":"10.1371\/journal.pone.0045587","article-title":"The monoamine Re-Uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset","volume":"7","author":"Huot","year":"2012","journal-title":"PLoS One"},{"issue":"194","key":"10.1016\/j.neuropharm.2018.06.038_bib19","article-title":"5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2018.06.038_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neuropharm.2014.01.012","article-title":"UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset","volume":"82","author":"Huot","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.06.038_bib21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.110.169532","article-title":"Fatty acid amide hydrolase (FAAH) inhibition reduces l-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned non-human primate model of Parkinson's disease","volume":"336","author":"Johnston","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib23","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1096\/fj.11-195016","article-title":"A\u00a0novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates","volume":"26","author":"Johnston","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0026-895X(25)12558-3","article-title":"Receptor-binding properties in\u00a0vitro and in\u00a0vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist","volume":"27","author":"Leysen","year":"1985","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1471-4159.2000.740693.x","article-title":"Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in\u00a0vivo dopamine outflow in the rat striatum","volume":"74","author":"Lucas","year":"2000","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib26","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00228-014-1772-0","article-title":"Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders","volume":"70","author":"Lutz","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00002826-198610000-00010","article-title":"Open pilot trial of ritanserin in parkinsonism","volume":"9","author":"Maertens de Noordhout","year":"1986","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib28","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00213-004-1817-7","article-title":"EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study","volume":"175","author":"Mamo","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.06.038_bib29","first-page":"262","article-title":"Controlled single-blind crossover study of ritanserin and placebo in L-dopa-induced dyskinesias in Parkinson's disease","volume":"43","author":"Meco","year":"1988","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib30","first-page":"39","article-title":"Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine","volume":"12","author":"Meltzer","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.06.038_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0166-4328(96)00111-8","article-title":"Ca2+ mobilizing agents mimic serotonin 5-HT2A facilitation of N-methyl-D-aspartate depolarization","volume":"73","author":"Neuman","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib32","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","article-title":"D1, D2, and 5\u2013HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients","volume":"152","author":"Nordstrom","year":"1995","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib33","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)","volume":"32","author":"Oertel","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib34","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib35","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1460-9568.2011.07675.x","article-title":"Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias","volume":"33","author":"Riahi","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib36","series-title":"Clinical Pharmacokinetics: Concepts and Application","author":"Rowland","year":"1995"},{"key":"10.1016\/j.neuropharm.2018.06.038_bib37","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropylo xy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib38","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","article-title":"A\u00a05-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model","volume":"90","author":"Vanover","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1124\/jpet.117.247171","article-title":"Predictive value of parkinsonian primates in pharmacologic studies: a comparison between the macaque, marmoset, and squirrel monkey","volume":"365","author":"Veyres","year":"2018","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2018.06.038_bib40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Meth. Progr. Biomed."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818303551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818303551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T13:30:46Z","timestamp":1751722246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818303551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":39,"alternative-id":["S0028390818303551"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.06.038","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}